Media Relations News Releases Year: - Any -202120202019201820172016 Items per page 102550 Aug 20, 2020 Summary ToggleFDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Aug 5, 2020 Summary ToggleNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis Jun 18, 2020 Summary ToggleNovartis expands Africa Sickle Cell Disease program to Uganda and Tanzania May 29, 2020 Summary ToggleNovartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation May 28, 2020 Summary ToggleNovartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS) May 14, 2020 Summary ToggleNovartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms Apr 21, 2020 Summary ToggleNovartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS) Jan 20, 2020 Summary ToggleNovartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease Dec 6, 2019 Summary ToggleNovartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy Nov 17, 2019 Summary ToggleNovartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
